Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in weight loss. These medications belong to a class of drugs known as GLP-1 ...

1月18日，国家医保局公示了国家医保药品目录的结果，我们发现受到临床高度关注的德谷胰岛素利拉鲁肽注射液（Insulin Degludec/Liraglutide Injection ...

Victoza（利拉鲁肽）是诺和诺德的一款重磅降糖药，其活性药物成分liraglutide（利拉鲁肽）是一种胰高血糖素样肽-1（GLP-1）受体激动剂，能够刺激天然 ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

This discovery may lead to a novel treatment approach that targets underlying brain pressure mechanisms rather than just ...

Liraglutide is a glucagon-like peptide 1 (GLP1) receptor agonist that is approved for the treatment of T2DM at doses up to 1.8 mg once daily 6.The moderate dose-dependent weight loss observed in ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Higher glycemia was associated with worse cognitive score outcomes among patients with short-duration type 2 diabetes at 4-year follow-up.

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy ...

New research reveals that liraglutide, a GLP-1 receptor agonist, crosses the blood-brain barrier to target specific neurons, reducing appetite and promoting lasting weight loss. Liraglutide, a ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...